Check the Low Dose Naltrexone (lowdosenaltrexone.org/ldn_and_ms) website
low-dose Naltrexone is a very cheap and effective therapy for many auto-immune diseases. It seems to be just as effective in MS.
It works by elevating endorphins, which are immune regulators as well as painkillers. You take a small dose at night (3mg for MS) and it temporarily blocks endorphin receptors while you sleep; the body makes more endorphin to compensate. It seems ridiculously simple, not to mention inexpensive. But when you consider that giving morphine (which has the opposite effect to naltrexone) after cancer surgery dramatically increases the chances of cancer returning (tramadol doesn't have this risk) you can see that there is a rational basis for it.
If I wasn't on methadone, I'd have taken LDN long ago. As it is I'm on a decreasing dose so I can take it in a few years time (if I took naltrexone now I'd just go into opioid withdrawals, as it would block the methadone at the receptors). I'm hoping that the reducing dose of methadone has some of the endorphin-stimulating effects of naltrexone.
I knew a guy who was on methadone and was diagnosed with a brain tumour, we all though he'd had it and were surprised that he came off methadone, instead of getting more drugs for his pain. But he's still alive and healthier than ever since withdrawing off opiates.
Here's some info from the low-dose naltrexone website:
The following excerpted posting, written by the chief pharmacist of Skip's Pharmacy of Boca Raton, Florida, appeared on a different website:
From: Dr. Skip
Subject: Naltrexone
Date: October 23, 2003
As I have said before, if I had MS, the only drug that I would absolutely be taking is LDN..... In 4 years of dispensing LDN, with over 10,000 patient months, I have heard of only three cases of exacerbation... this is truly a no-brainer. I would find someone to prescribe it no matter the cost or effort.
Skip Lenz, Pharm. D.
Naltrexone was licensed in 1984 by the FDA in a 50 mg dose as a treatment for heroin addiction. It is a pure opiate antagonist (blocking agent) and its purpose was to block the opioid receptors that heroin acts on in the brain. When it was licensed, Dr. Bihari, then involved in running programs for treating addiction, tried it in more than 50 heroin addicts who had stopped heroin use. None of the patients would stay on the drug because of side effects experienced at 50 mg such as insomnia, depression, irritability and loss of feelings of pleasure, all due to the effect of the drug at this dose in blocking endorphins. These are the hormones in the body that heroin resembles. Physicians treating heroin addicts therefore, for the most part, stopped prescribing naltrexone. In 1985, a large number of heroin addicts began to get sick with AIDS-studies showed that 50% of heroin addicts were HIV Positive.
Dr. Bihari and his colleagues decided to shift their research focus to AIDS, in particular focusing on ways of strengthening the immune system. Since endorphins are the hormones centrally involved in supporting and regulating the immune system, levels of endorphins were measured in the blood of AIDS patients. They were found to average only 25% of normal.
Naltrexone, when given to mice and people at high doses, raises endorphin levels in the body's effort to overcome the naltrexone blockade. This drug became the focus of Dr. Bihari's research group. When the group discovered that endorphins are almost all produced in the middle of the night, between 2 AM and 4 AM, the studies focused on small doses (1.5-4.5 mg at bedtime) with the hope that a brief period of endorphin blockade before 2 AM might induce an increase in the body's endorphin production. In fact, the drug did so in this dosage range. It had no effect below 1.5 mg and too much endorphin blockade at doses over 5 mg. A placebo-controlled trial in AIDS patients showed a markedly better outcome in patients on the drug as compared with t